Latest market price
32.47
-3.86-10.62%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -3.43 | Insider Own | 15.93% | Shs Outstand | 134.37M | Perf Week | -9.00% |
| Market Cap | 4.36B | Forward P/E | — | EPS next Y | -2.05 | Insider Trans | -0.65% | Shs Float | 126.99M | Perf Month | -13.18% |
| Enterprise Value | 3.31B | PEG | — | EPS next Q | -0.56 | Short Float | 7.91% | Perf Quarter | -23.28% | ||
| Income | -353.00M | P/S | — | EPS this Y | — | Short Ratio | 4.72 | Perf Half Y | 49.29% | ||
| Sales | 0.00 | P/B | 4.75 | EPS next Y | — | ROA | -31.79% | Short Interest | 10.04M | Perf YTD | 142.49% |
| Book/sh | 6.84 | P/C | 4.02 | EPS next 5Y | — | ROE | -85.23% | 52W High | 49.70 -34.67% | Perf Year | 142.49% |
| Cash/sh | 8.07 | P/FCF | — | EPS past 3/5Y | — | ROIC | -23.81% | 52W Low | 10.46 210.42% | Perf 3Y | 1153.67% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 6.95% 5.26% | Perf 5Y | -10.18% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 2.05 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 6.95 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 37.37 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 6.95 | EPS Q/Q | -188.00% | SMA20 | -7.86% | Beta | 2.23 | Target Price | 67.45 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | — | SMA50 | -13.46% | Rel Volume | 1.67 | Prev Close | 36.33 |
| Employees | 106 | LT Debt/Eq | 0.04 | Earnings | Nov 09 | SMA200 | 9.37% | Avg Volume | 2.19M | Price | 32.47 |
| IPO Date | Nov 15, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -166.16% — | Net Debt/EBITDA | — | Volume | 3,645,207 | Change | -10.62% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-15-26 | Reiterated | UBS | $70 | |
| Sep-15-26 | Reiterated | Robert W. Baird | $75 → $79 | |
| Sep-15-26 | Reiterated | Canaccord Genuity | Buy | $64 → $78 |
| Sep-14-26 | Reiterated | Oppenheimer | Outperform | $70 → $75 |
| Aug-14-26 | Reiterated | Maxim Group | Buy | $55 |
| Aug-13-26 | Reiterated | Robert W. Baird | $57 → $75 | |
| Aug-13-26 | Reiterated | Canaccord Genuity | Buy | $58 → $64 |
| Aug-12-26 | Reiterated | Oppenheimer | Outperform | $60 → $70 |
| Aug-12-26 | Reiterated | Needham | Buy | $50 → $66 |
| Jul-27-26 | Initiated | Wells Fargo | Overweight | $68 |
Latest News· Times ET
Oct-27-26
Oct-27-2609:11PM
Oct-26-26
Oct-22-26
Oct-22-2602:28AM
Oct-21-26
Oct-19-26
Oct-13-26
Oct-09-26
Oct-09-2611:11AM
Sep-30-26
Sep-28-26
Sep-24-26
Sep-24-2602:02AM
Sep-21-26
Sep-19-26
Sep-15-26
Sep-14-26
Company
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 8/31/2019 | FY 2018 8/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 1 | 3 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | -1 | -3 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 73 | 49 | 39 | 42 | — | — | — | — | — | |
| Research and Development | 155 | 118 | 65 | 49 | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | -1 | 0 | — | — | — | — | — | |
| Operating Income | -228 | -166 | -104 | -94 | — | — | — | — | — | |
| Interest Expense | 13 | 5 | 2 | 1 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -113 | -12 | -2 | -1 | — | — | — | — | — | |
| Net Income Before Taxes | -353 | -184 | -109 | -96 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -353 | -184 | -109 | -96 | — | — | — | — | — | |
| Net Income From Continuing Operations | -353 | -184 | -109 | -96 | — | — | — | — | — | |
| Net Income | -353 | -184 | -109 | -96 | — | — | — | — | — | |
| EPS (Recurring) | -3.44 | -2.06 | -1.54 | -2.44 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.44 | -2.06 | -1.54 | -2.44 | — | — | — | — | — | |
| EPS (Diluted) | -3.43 | -2.06 | -0.15 | -2.44 | — | — | — | — | — | |
| EBITDA | -340 | -178 | -106 | -93 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 111 | 89 | 70 | 39 | — | — | — | — | — | |
| Market Capitalization | 3,604 | 1,192 | 487 | 143 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wiley Matthew T. | Chief Commercial Officer | Sep 25 '26 | Sale | 36.57 | 3,097 | 113,257 | 359,036 | Sep 29 |
| Barrow Robert | Chief Executive Officer | Sep 25 '26 | Sale | 36.57 | 31,550 | 1,153,784 | 2,213,090 | Sep 29 |
| Sullivan Mark | Chief Legal Officer | Sep 25 '26 | Sale | 36.57 | 14,051 | 513,845 | 494,228 | Sep 29 |
| Roberts Brandi | Chief Financial Officer | Sep 25 '26 | Sale | 36.57 | 3,377 | 123,497 | 394,528 | Sep 29 |
| Karlin Daniel | Chief Medical Officer | Sep 25 '26 | Sale | 36.57 | 10,853 | 396,894 | 792,846 | Sep 29 |
| Krebs Andreas | Director | Sep 18 '26 | Option Exercise | 35.52 | 1,629 | 57,862 | 21,402 | Sep 18 |
| Vallone Carol A | Director | Sep 18 '26 | Option Exercise | 35.52 | 1,086 | 38,575 | 22,296 | Sep 18 |
| Barrow Robert | Chief Executive Officer | Sep 03 '26 | Sale | 37.94 | 19,023 | 721,733 | 1,494,640 | Sep 04 |
| Sullivan Mark | Chief Legal Officer | Jun 25 '26 | Sale | 45.03 | 13,008 | 585,750 | 320,571 | Jun 26 |
| Roberts Brandi | Chief Financial Officer | Jun 25 '26 | Sale | 45.03 | 3,013 | 135,675 | 209,487 | Jun 26 |
| Barrow Robert | Chief Executive Officer | Jun 25 '26 | Sale | 45.03 | 29,208 | 1,315,236 | 1,098,246 | Jun 26 |
| Karlin Daniel | Chief Medical Officer | Jun 25 '26 | Sale | 45.03 | 10,035 | 451,876 | 503,282 | Jun 26 |
| Wiley Matthew T. | Chief Commercial Officer | Jun 25 '26 | Sale | 45.03 | 2,867 | 129,101 | 174,633 | Jun 26 |
| Karlin Daniel | Chief Medical Officer | Mar 25 '26 | Sale | 18.47 | 8,018 | 148,092 | 413,317 | Mar 26 |
| Sullivan Mark | Chief Legal Officer | Mar 25 '26 | Sale | 18.47 | 10,702 | 197,666 | 271,079 | Mar 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.